Infectious Disease

Siemens Healthineers offers a broad portfolio of infectious disease (ID) testing capabilities across diagnostic disciplines, from screening and diagnosis to genotyping, therapy and monitoring.

Identificação precisa da resposta imune para apoiar o gerenciamento a longo prazo do COVID-19

Ensaio IgG para detecção do SARS-CoV-2

Alta especificidade para identificação precisa da resposta imune
Ensaio para a  detecção de anticorpos totais contra o  SARS-CoV-2 da Siemens Healthineers

SARS-CoV-2 – Dosagem de Anticorpos Totais

Detecta anticorpos totais (IgM e IgG) com alta sensibilidade
Jim Freeman

Educational Video: Behind the design of the Siemens Healthineers SARS-CoV-2 Total Assay

Hear from Jim Freeman, the Vice President of Research and Development, Global Immunoassay Development at Siemens Healthineers
Infographic: Build programs to more safely and efficiently reopen communities, businesses and schools

Infographic: Testing is key to reopening

There are numerous tests to help detect SARS-CoV-2 virus or antibodies to the virus. Only a few are highly accurate.
Specificity Matters

Why Specificity Matters in COVID-19 antibody testing

Learn why specificity matters for antibody testing during the COVID-19 pandemic
Papel dos testes sorológicos no COVID-19

Papel dos testes sorológicos no COVID-19

Reconhecendo a necessidade crítica de testes de diagnóstico precisos para gerenciar o COVID-19, desenvolvemos um teste total de anticorpos para detectar anticorpos IgM e IgG contra SARS-CoV-2 no sangue. *
FTD SARS-CoV-2 Assay (RUO)

FTD SARS-CoV-2 Assay

For the identification of the coronavirus causing COVID-19.
TORCH and Special ID Assay menu

TORCH and Special ID Assays

Make automated infectious-disease screening part of your routine testing
Healthy Mother/Healthy Baby Thought Leadership Webinar Series

Webinar: Optimal Pregnancy Outcomes through Proper ID Testing

Explore our AACC Healthy Mother/Healthy Baby Thought Leadership Webinar Series
ADVIA Centaur Zika Test

ADVIA Centaur Zika Test

An automated Zika test to detect IgM antibodies to the Zika Virus
Antibody testing satisfies FDA requirement for SARS-CoV-2 vaccine development

Siemens Healthineers antibody assays meet and exceed FDA EUA guidance for assessment of immune response

Learn how antibody testing satisfies FDA requirement for SARS-CoV-2 vaccine development

Compartilhe esta página:

O produto/recurso exibido nesta página Web não está comercialmente disponível em todos os países. Por razões de regulamentação, sua disponibilidade futura não pode ser garantida. Por favor, entre em contato com a organização da Siemens local para maiores detalhes.

*This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.

1For research use only (RUO). Pursuing FDA emergency use authorization (EUA). Pursuing WHO emergency use assessment and listing (EUAL) certification.